Management in Relapsed/Refractory Follicular Lymphoma – Dr. Stefano Luminari
Unmet needs exist in the R/R setting. In the future, more randomized trials are needed to improve the quality of evidence. It will also be important to define therapy use for patients who are refractory to r-bendamustine. Improvements are also possible through a personalized approach. In low-risk patients (70-80%), the goal is to do no harm, versus in high-risk patients (20-30%), early identification is needed, as well as novel therapies and targets.
We will soon move towards an era of targeted agents in FL. There are many promising therapies already being investigated in clinical trials, such as P13K inhibitors (ie. idelalisib), immunomodulatory agents (ie. lenalidomide), proteasome inhibitors (ie bortezomib), BCL2 inhibitors (venetoclax), anti-PD1 inhibitors (ie. nivolumab, pembrolizumab, etc.) and BTK inhibitors (ie. ibrutinib, acalabrutinib).
Click here to view Dr. Stefano Luminari’s presentation from CHC 2016.